Median age at inclusion (years) | 66 | [39–85] |
Performance status | ||
0 | 39 | 37.9% |
1 | 46 | 44.7% |
2 | 11 | 10.7% |
3 | 2 | 1.9% |
NA | 3 | 2.9% |
BMI (kg/m2) | 27 | [18.3–56.5] |
HER2 status | ||
Positive | 9 | 8.7% |
Negative | 90 | 87.4% |
NA | 4 | 3.9% |
Disease presentation at metastatic setting* | ||
De novo | 53 | 51.4% |
Relapsed | 50 | 48.6% |
Adjuvant treatment | ||
Chemotherapy | 37 | 74.0% |
Hormonotherapy | 44 | 88.0% |
Tamoxifen | 34 | 77.3% |
AI | 25 | 56.8% |
Median delay from end of adjuvant treatment to metastatic diagnostic (months) | 57.5 | [37–107] |
Metastatic treatment before AI introduction | ||
Chemotherapy | ||
Yes | 26 | 25.2% |
No | 77 | 74.8% |
Endocrine therapy except AI | ||
Yes | 13 | 12.6% |
No | 90 | 87.4% |
AI status at inclusion | ||
Initiation at inclusion | 75 | 72.8% |
Already started without progression | 28 | 27.2% |
Median delay since AI introduction (months) | 9.9 | [6.2–63.8] |
Median follow-up (months) | 25.3 | [3–92] |